|Day Low/High||85.46 / 86.86|
|52 Wk Low/High||62.55 / 101.28|
The Food and Drug Administration warns of serious liver injury risk with AbbVie's (ABBV) hepatitis C treatments, Viekira Pak and Technivie. The stock is down by more than 12% on the news.
Put cash to work in large-caps that have become cheap in the current market.
I'll continue to add to Amgen, Teva and AbbVie incrementally as recent selloffs seem unwarranted.
One of my favorite topics over the last few quarters has been stock-buyback programs. Companies like Apple (AAPL) have floated cheap debt to fund buyback programs and other things. I get it -- it's far cheaper to offer debt than perhaps deal with re...
Just as the offensive line is vital to a team's success, so are consistent performers in a portfolio.
China, and Fed rate hike uncertainty, continue to drive volatility.
The next couple of sessions offer an opportunity to nibble at four names with lower entry points.
Have your shopping list of stocks handy in case markets tank again.
Shire (SHPG) has announced an offer to buy Baxalta (BXLT), a rare disease treatment specialist based in the U.S., for around $30.6 billion in stock.
For Friday July 24, TheStreet awaits quarterly financial results from Biogen (BIIB), AbbVie (ABBV), American Airlines Group (AAL), and Spirit Airlines (SAVE).
For the week of July 20, TheStreet outlines the key earnings reports and economic data to watch on Wall Street.
These stocks will be up so high today, that many fans will say "no thanks."
This market is almost entirely special situation.
Duke Energy's recent increase puts its payout at the high end of the industry range.
The biotech's stock has likely peaked, as increased competition awaits in the Hep-C space.
The ABBV chart looks constructive, with solid volume and bullish indicators.
Jim Cramer reveals why his Action Alerts PLUS charitable trust portfolio is initiating coverage of Johnson & Johnson (JNJ) on Tuesday.